Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals
Reisa A. Sperling(Brigham and Women's Hospital), Michael J. Pontecorvo, Carl Sadowsky(Nova Southeastern University), Mat D. Davis(Clinical Research Institute), Daniel Skovronsky, Eric M. Reiman(Alzheimer's Association), Matthew Flitter, Adam Fleisher(Banner Alzheimer’s Institute), Michael Grundman(University of San Diego), Mark A. Mintun(Eli Lilly (United States)), Ming‐Chi Lu(University of California, San Francisco), Keith A. Johnson(Jacobson Holman (United States)), Christopher M. Clark(University of Pennsylvania), Marwan N. Sabbagh(Cleveland Clinic), Alan Carpenter, P. Murali Doraiswamy(Duke Medical Center), Abhinay D. Joshi
Cited by 127
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k